Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment

Purpose The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2019-08, Vol.28 (8), p.1054-1059
1. Verfasser: Friberg, Leif
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1059
container_issue 8
container_start_page 1054
container_title Pharmacoepidemiology and drug safety
container_volume 28
creator Friberg, Leif
description Purpose The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation. Methods All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods. Results Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used. Conclusions Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies.
doi_str_mv 10.1002/pds.4793
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232067409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2267682530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</originalsourceid><addsrcrecordid>eNp1kc2KFTEQhYMozjgKPoEE3LjpMX-d7ixlxj8YUBhdN-l05Zq53UmbSqP3NXxic51RQXBVxclXh6ocQp5yds4ZEy_XCc9VZ-Q9csqZMQ1v2-7-sW9l07fanJBHiDeM1TejHpITyTkXUvNT8uP6S8qFzintR-v2dIUc0oTU2Q1D3FH4bnc7yLbARLHktAeaA-4pYAlLVZGGSG3Jwc7UhzGHebYlpEgXe6jDa0Kga1UgFqQl0S1GcIBo84HaWIJLdrfNtaMlgy1L5R6TB97OCE_u6hn5_Ob1p4t3zdWHt-8vXl01Tiojm9bbkemRc-VNFXSvve-1BTX5TmijOimZmCRYodnUTm3PdK8cqLHzrnfWyTPy4tZ3zenrVg8aloAO6gER0oaDEFIw3SlmKvr8H_QmbTnW7SqlO92LVrK_hi4nxAx-WHP9pHwYOBuOOQ01p-GYU0Wf3Rlu4wLTH_B3MBVoboFvYYbDf42Gj5fXvwx_ApIEn6E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2267682530</pqid></control><display><type>article</type><title>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Friberg, Leif</creator><creatorcontrib>Friberg, Leif</creatorcontrib><description>Purpose The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation. Methods All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods. Results Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used. Conclusions Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.4793</identifier><identifier>PMID: 31112361</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Anticoagulants ; Anticoagulants - administration &amp; dosage ; atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Brain Ischemia - epidemiology ; Brain Ischemia - etiology ; Brain Ischemia - prevention &amp; control ; Cardiac arrhythmia ; CHA2DS2‐VASc ; Congestive heart failure ; Diabetes ; Diabetes mellitus ; epidemiology ; Female ; Fibrillation ; Follow-Up Studies ; Health risks ; Heart failure ; Humans ; Hypertension ; Male ; Patients ; pharmacoepidemiology ; Registries ; Risk Factors ; risk stratification ; Stroke ; Stroke - epidemiology ; Stroke - etiology ; Stroke - prevention &amp; control ; Sweden ; Thromboembolism ; Time Factors ; Unnecessary Procedures ; Vascular diseases</subject><ispartof>Pharmacoepidemiology and drug safety, 2019-08, Vol.28 (8), p.1054-1059</ispartof><rights>2019 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</citedby><cites>FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</cites><orcidid>0000-0002-7453-0157</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.4793$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.4793$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31112361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Friberg, Leif</creatorcontrib><title>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation. Methods All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods. Results Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used. Conclusions Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies.</description><subject>Aged</subject><subject>Anticoagulants</subject><subject>Anticoagulants - administration &amp; dosage</subject><subject>atrial fibrillation</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Brain Ischemia - epidemiology</subject><subject>Brain Ischemia - etiology</subject><subject>Brain Ischemia - prevention &amp; control</subject><subject>Cardiac arrhythmia</subject><subject>CHA2DS2‐VASc</subject><subject>Congestive heart failure</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>epidemiology</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Follow-Up Studies</subject><subject>Health risks</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Male</subject><subject>Patients</subject><subject>pharmacoepidemiology</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>risk stratification</subject><subject>Stroke</subject><subject>Stroke - epidemiology</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention &amp; control</subject><subject>Sweden</subject><subject>Thromboembolism</subject><subject>Time Factors</subject><subject>Unnecessary Procedures</subject><subject>Vascular diseases</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc2KFTEQhYMozjgKPoEE3LjpMX-d7ixlxj8YUBhdN-l05Zq53UmbSqP3NXxic51RQXBVxclXh6ocQp5yds4ZEy_XCc9VZ-Q9csqZMQ1v2-7-sW9l07fanJBHiDeM1TejHpITyTkXUvNT8uP6S8qFzintR-v2dIUc0oTU2Q1D3FH4bnc7yLbARLHktAeaA-4pYAlLVZGGSG3Jwc7UhzGHebYlpEgXe6jDa0Kga1UgFqQl0S1GcIBo84HaWIJLdrfNtaMlgy1L5R6TB97OCE_u6hn5_Ob1p4t3zdWHt-8vXl01Tiojm9bbkemRc-VNFXSvve-1BTX5TmijOimZmCRYodnUTm3PdK8cqLHzrnfWyTPy4tZ3zenrVg8aloAO6gER0oaDEFIw3SlmKvr8H_QmbTnW7SqlO92LVrK_hi4nxAx-WHP9pHwYOBuOOQ01p-GYU0Wf3Rlu4wLTH_B3MBVoboFvYYbDf42Gj5fXvwx_ApIEn6E</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Friberg, Leif</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7453-0157</orcidid></search><sort><creationdate>201908</creationdate><title>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</title><author>Friberg, Leif</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3493-5fab06b114f9349686ff86ae4df7269473302d3ea260d5d580684ce4b7fc8cac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Anticoagulants</topic><topic>Anticoagulants - administration &amp; dosage</topic><topic>atrial fibrillation</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Brain Ischemia - epidemiology</topic><topic>Brain Ischemia - etiology</topic><topic>Brain Ischemia - prevention &amp; control</topic><topic>Cardiac arrhythmia</topic><topic>CHA2DS2‐VASc</topic><topic>Congestive heart failure</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>epidemiology</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Follow-Up Studies</topic><topic>Health risks</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Male</topic><topic>Patients</topic><topic>pharmacoepidemiology</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>risk stratification</topic><topic>Stroke</topic><topic>Stroke - epidemiology</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention &amp; control</topic><topic>Sweden</topic><topic>Thromboembolism</topic><topic>Time Factors</topic><topic>Unnecessary Procedures</topic><topic>Vascular diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Friberg, Leif</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Friberg, Leif</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2019-08</date><risdate>2019</risdate><volume>28</volume><issue>8</issue><spage>1054</spage><epage>1059</epage><pages>1054-1059</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose The purpose was to investigate how different lookback periods in observational registry studies affect estimates of stroke risk in patients with atrial fibrillation and stroke risk score CHA2DS2‐VASc 1, a level where the appreciated risk is likely to affect decisions about oral anticoagulation. Methods All 354 854 individuals in Sweden with a hospital diagnosis of atrial fibrillation during 2010‐2016 were included. At least 13 years of observational data prior to inclusion was available for all patients. The prevalence of hypertension, heart failure, diabetes, previous thromboembolism, and vascular disease was estimated from data with different lookback periods. The incident stroke rates at CHA2DS2‐VASc score 1 was then assessed using data with successively longer lookback periods. Results Depending on duration of lookback period, the proportion of patients with heart failure varied 2.7 times, thromboembolism 3.7 times, hypertension 4.0 times, and diabetes and vascular disease both approximately 4.5 times. During follow‐up, 22 237 patients suffered an ischaemic stroke. The estimated risk without anticoagulant treatment at CHA2DS2‐VASc score 1 was 51% higher if the scores had been calculated with the shortest lookback period than if all information had been used. Conclusions Short lookback periods underestimate comorbidity, cause high‐risk patients to be misclassified as low risk, and overestimate stroke risk at CHA2DS2‐VASc 1. This may lead to unnecessary anticoagulant treatment of true low‐risk patients. Transparency regarding lookback periods is essential for interpretation and comparison of registry studies.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31112361</pmid><doi>10.1002/pds.4793</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7453-0157</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1053-8569
ispartof Pharmacoepidemiology and drug safety, 2019-08, Vol.28 (8), p.1054-1059
issn 1053-8569
1099-1557
language eng
recordid cdi_proquest_miscellaneous_2232067409
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Aged
Anticoagulants
Anticoagulants - administration & dosage
atrial fibrillation
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Brain Ischemia - epidemiology
Brain Ischemia - etiology
Brain Ischemia - prevention & control
Cardiac arrhythmia
CHA2DS2‐VASc
Congestive heart failure
Diabetes
Diabetes mellitus
epidemiology
Female
Fibrillation
Follow-Up Studies
Health risks
Heart failure
Humans
Hypertension
Male
Patients
pharmacoepidemiology
Registries
Risk Factors
risk stratification
Stroke
Stroke - epidemiology
Stroke - etiology
Stroke - prevention & control
Sweden
Thromboembolism
Time Factors
Unnecessary Procedures
Vascular diseases
title Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A55%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20lookback%20periods%20causing%20exaggerated%20stroke%20risk%20estimates%20in%20atrial%20fibrillation%20may%20expose%20patients%20to%20unnecessary%20anticoagulant%20treatment&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Friberg,%20Leif&rft.date=2019-08&rft.volume=28&rft.issue=8&rft.spage=1054&rft.epage=1059&rft.pages=1054-1059&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.4793&rft_dat=%3Cproquest_cross%3E2267682530%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2267682530&rft_id=info:pmid/31112361&rfr_iscdi=true